Axsome Therapeutics, Inc. Share Price & Technical Analysis
AXSM · $236.0 (+1.00%)
Healthcare / Biotechnology
$236.0
+1.00%
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment …
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
14% return in May, -1% avg return in past 3 year May month.
29% return in 2026, 39% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | -11% | 4% | 22% | 14% | – | – | – | – | – | – | – | 29% |
| 25 | 25% | 20% | -10% | 0% | -5% | -1% | -2% | 20% | 0% | 10% | 22% | 22% | 100% |
| 24 | 15% | -10% | -2% | -8% | -1% | 8% | 9% | 1% | 0% | -1% | 10% | -13% | 9% |
| 23 | -3% | -9% | -9% | 16% | 3% | -3% | 9% | 3% | -14% | -11% | 9% | 18% | 7% |
| 22 | -28% | 3% | 44% | -24% | -20% | 52% | 1% | 66% | -29% | -1% | 57% | 7% | 129% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$11.47B
P/E ratio
—
52W high
$236.8
52W low
$96.09
Volume
6,74,622
Beta
0.58
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Axsome Therapeutics, Inc. share price today?
- Axsome Therapeutics, Inc. (AXSM) last traded around $236.0 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does AXSM have?
- StockPro currently tracks 1 active signal(s) for AXSM, including breakouts, momentum, and volume patterns. See the signals panel on this page.
- How can I analyze Axsome Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.